Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Summary

This trial aim to explore whether short-course tislelizumab (3 cycles of 200 mg q3w in the induction phase and 3 cycles of 400 mg q6w in the consolidation phase) yields non-inferior event-free survival compared to long-course tislelizumab (3 cycles of 200 mg q3w in the induction phase and 5 cycles of 400 mg q6w in the consolidation phase) in patients with locoregionally advanced nasopharyngeal carcinoma.

Timeline

Start

2026-01-15

Primary completion

2028-04-30

Completion

2030-12-31

Drugs

Indications